Latest Breaking News On - Surface oncology - Page 24 : vimarsana.com

12 05 22 -- Listen now: Oligonucleotide Therapy Delivery, Product vs Platform, and more

12/05/22 Life Science Leader Newsletter

United statesUnited kingdomVito palombellaPeter demuthRob rossGeoff nosratiAmphiphile technology platformZakari therapeuticsSurface oncologyElicio therapeutic

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

14.11.2022 - Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient .

United kingdomJohn mullalyNeuroinflammation evansMaurice zaudererPepinemab trastuzumabLifesci advisorsVaccinex incSociety for immunotherapy of cancerWinship cancer institute of emory universityExchange commissionDevelopment expensesHuntington study groupActivmab platform technologyEuropean huntington disease networkAssociation international conferenceEuropean society for medical oncology

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United kingdomRob rossScott youngInterferon societyDrug administrationExchange commissionCytokines meeting of the international cytokineInflammation researchGhent centerClinical program updatesSurface oncologyInvestigational new drugSubsequent corporateStructural biologyAnnual cytokines meetingInternational cytokine

Surface Oncology to lay off 20% of staff in restructuring

BioPharma

Rob rossBiomarin pharmaceuticalsBiotechnology innovation organizationSurface oncologyBiotechnology innovationRubius therapeuticsVesalius therapeutics

Surface Oncology trims workforce by 20%

Surface Oncology management stated Wednesday that its financial runway is now sufficient to get into Q2 2024.

Rob rossDrug administrationSurface oncologyOrphan drug